MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma
Carmen González, Camila Guerrero, Marta Larráyoz, Aintzane Zabaleta et autres
0 citationsBlood
Aintzane Zabaleta
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
166Publications signalées
2013Citations signalées
5Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses
Publications récentes
Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma
Thomas E. Kraft, Estelle Marrer‐Berger, Sara Belli, Hélène Haegel et autres
0 citationsClinical Pharmacology & Therapeutics
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma
Lorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, María Eréndira Calleja-Cervantes et autres
2 citationsBlood Neoplasia
Immune biomarkers of increased infection risk in multiple myeloma
Aintzane Zabaleta, Luis‐Esteban Tamariz‐Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis Pistofidis et autres
4 citationsBlood
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
Tomas Jelinek, David Žihala, Aintzane Zabaleta, Ioannis V. Kostopoulos et autres
15 citationsBlood
The origin of autoimmune diseases: is there a role for ancestral HLA-II haplotypes in immune hyperactivity
Manuel Ruiz-Pablos, Bruno Paiva, Aintzane Zabaleta
7 citationsFrontiers in Immunology
iMMune profiling comes of age
Bruno Paiva, Aintzane Zabaleta
0 citationsBlood
Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study
Marta Lasa, Esperanza Martín‐Sánchez, Aintzane Zabaleta, Diego Alignani et autres
0 citationsBlood
Immune biomarkers of increased risk of infection in multiple myeloma (MM)
Aintzane Zabaleta, Luis‐Esteban Tamariz‐Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis‐Pistofidis et autres
0 citationsBlood
Measurable Residual Disease (MRD) Dynamics Reveals a Therapeutic Vulnerability State for Early Immunotherapy Interception in Multiple Myeloma (MM)
Noelia Collado-Gisbert, Camila Guerrero, Marta Larráyoz, Aintzane Zabaleta et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Absolute Lymphocyte Count (ALC) ≥1,000 IS AS A Surrogate of Car-T Cell Expansion and a Readily Available Biomarker to Predict Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM)
Luis‐Esteban Tamariz‐Amador, Ana Alfonso Piérola, Aintzane Zabaleta, Sofía Huerga-Domínguez et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple Myeloma
Lorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, María Eréndira Calleja-Cervantes et autres
1 citationbioRxiv (Cold Spring Harbor Laboratory)
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.